SAFRAZINE HYDROCHLORIDE

Details

Stereochemistry	RACEMIC
Molecular Formula	C11H16N2O2.ClH
Molecular Weight	244.718
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CC(CCC1=CC=C2OCOC2=C1)NN

InChI

InChIKey=UOZNXVYMTZITGP-UHFFFAOYSA-N

InChI=1S/C11H16N2O2.ClH/c1-8(13-12)2-3-9-4-5-10-11(6-9)15-7-14-10;/h4-6,8,13H,2-3,7,12H2,1H3;1H

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C11H16N2O2
Molecular Weight	208.2569
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.drugbank.ca/drugs/DB09253 | https://www.ncbi.nlm.nih.gov/pubmed/8741286 | https://www.ncbi.nlm.nih.gov/pubmed/3339341

Safrazine (Safra) is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class that was introduced as an antidepressant in the 1960s. Safrazine and electroconvulsive therapy were shown to be effective in the treatment of antidepressant-resistant depressions (ARD) but had the drawbacks of the high incidence of moderate or severe adverse reactions and high relapse rates, respectively. The use of safrazine was discontinued.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Monoamine oxidase 32 Target ID: CHEMBL2095205 Sources: https://www.ncbi.nlm.nih.gov/pubmed/477139	Inhibitor 8504

PubMed

Title	Date	PubMed
Comparative studies of the effects of RS-8359 and safrazine on monoamine oxidase in-vitro and in-vivo in mouse brain.	1989-01	2565961

Sample Use Guides

In Vivo Use Guide

Nocturnal periodic hypoxemia occurring in a 25-year-old Duchenne muscular dystrophy patient under NIPPV control was successfully treated with monoamine oxydase inhibitor (MAOI), safrazine hydrochloride. Five mg of safrazine hydrochloride was administered before sleep, and the periodic hypoxemia disappeared within 14 days.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:26:56 GMT 2025` Edited by `admin` on `Mon Mar 31 18:26:56 GMT 2025`
Record UNII	5985O24GLM
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SAFRAZINE HYDROCHLORIDE

Common Name

English

SAFRAZINE HYDROCHLORIDE [JAN]

Preferred Name

English

SAFRAZINE HCL

Common Name

English

SAFRAZINE HYDROCHLORIDE [MART.]

Common Name

English

Safrazine hydrochloride [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C667